Johnson & Johnson

  • Pharmacyclics Set to Glide Higher

    By Terry Chrisomalis - July 31, 2013 | Tickers: BIIB, JNJ, PCYC

    Pharmacyclics (NASDAQ: PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per share. That's not to say it is too late, because this biotech company still has a lot of room to run higher. The reason for the continued run up will be the pipeline that continues to produce results. All of the candidates in more »

  • Is This Company Getting Ahead of Itself?

    By Nicholas Kitonyi - July 30, 2013 | Tickers: LLY, JNJ, NVS, PFE

    The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive. In the most recent quarter, biotech company Eli Lilly (NYSE: LLY) reported earnings that beat analyst estimates and boosted guidance for the next quarter and the current fiscal year.

    The company is counting on various products in the pipeline, which could change its outlook more »

  • The 3 Reasons Why This Industrial Giant Is Outperforming

    By Lee Samaha - July 29, 2013 | Tickers: AA, GE, JNJ

    If you think that investing is simple, then just take a look at industrial giant General Electric’s (NYSE: GE) latest results. The industrial sector has been weaker this year, but GE reported a surprisingly good set of results. Furthermore, rivals such as Switzerland’s ABB and Germany’s Siemens, have subsequently given disappointing results and guidance. So what's going on with GE? How has it managed to achieve more »

  • 3 Reasons GlaxoSmithKline Will Survive the China Scandal

    By Anjum Khan - July 29, 2013 | Tickers: GSK, JNJ, MRK

    GlaxoSmithKline (NYSE: GSK) has been accused of the violation of Chinese laws wherein the company’s key officials have used around 700 agencies and firms for increasing the sales and prices of drugs by bribing hospitals and doctors in China. The company has transferred around $489 million to these agencies. Four of the company’s executives are detained. This includes the vice president, the legal affairs director, the business development more »

  • Play the Rising Population With These Companies

    By Justin Pope - July 29, 2013 | Tickers: XOM, JNJ, WFM

    Here is a statistic for you - the human population is rising by 200,000 people per day. For a lot of companies, that means 200,000 new potential customers. You can use this to your advantage when looking for companies to invest in for the long term.

    Some industries will directly benefit from a growing population. Let's look at some sectors tied directly to the human population, and some more »

  • Why You Should Buy Dividend Stocks Instead of Bonds

    By Bob Ciura - July 29, 2013 | Tickers: KO, XOM, JNJ

    As the stock market creeps toward fresh all-time highs, it’s understandable for investors to get a little nervous. After all, it seems like only yesterday the entire financial system was in danger of collapse. Surely, investors haunted by memories of bank bailouts, the collapsing housing market, and the Dow free-falling toward 6,000 points, can’t help but think twice before committing capital to this market.

    Naturally, skittish investors more »

  • Will Healthcare Take Care of Your Portfolio

    By Madhukar Dubey - July 29, 2013 | Tickers: JNJ, MRK, PFE

    During the past decade, healthcare has been one of the most stable and consistent performers among all industries. According to IMS, global spending on healthcare during 2011-2016 is expected to grow at a CAGR of around 6%. The volume growth in emerging markets for pharmaceutical companies and continuous uptick in medicine spending in developed countries should drive global growth.

    Here are three health-care companies ready to capitalize on growth opportunities more »

  • Does Royal Baby Mean Royal Profits?

    By Gerelyn Terzo - July 26, 2013 | Tickers: JNJ, KMB, PG

    It's impossible to watch the news without hearing the royal buzz surrounding Prince William and Kate Middleton's new baby boy. Whether you care or not, it's hard not to feel some joy at the thought of a new and healthy baby being brought into the world. And whether or not the royal news gives way to a new baby boom, you can't ignore that the world more »

  • Don’t Miss These Leading Pharma Companies

    By Shweta Dubey - July 26, 2013 | Tickers: BMY, JNJ, PFE

    A recent EvaluatePharma report estimated the drug market of prescribed drugs to increase at CAGR of 3.8% to $895 billion between 2012-2018. New patents and improvement in research and development will be the key factors driving the market size of drugs. With the growth of drug market, pharmaceutical companies are in better position to monetize it. Three such pharmaceutical companies should be of interest to investors. These companies have more »

  • Is This Health-Care Giant Still a Good Value?

    By Lee Samaha - July 23, 2013 | Tickers: COV, JNJ, COO, VAR

    Investors in health-care giant Johnson & Johnson (NYSE: JNJ) have been rewarded with a 30% share price rise in the last year. The health-care giant remains a go-to choice for investors seeking a relatively recession-proof stock with a decent dividend. However, investors need to ask themselves a few questions about its recent results: Can this share price run continue?  Does Johnson & Johnson still provide compelling value?  And what are the key more »

  • These Stocks Belong in Your IRA

    By Justin Pope - July 23, 2013 | Tickers: XOM, JNJ, MCD

    Most people under the age of 35 don't put a lot of thought into their retirement. These people couldn't be more misguided. The power of compounding is the best tool an investor can have.

    To add some frosting to the cake – combining a tax sheltered investment vehicle with say 20, 30, or 40 years of time to grow those investments can make a young person very rich later more »

  • This Health Care Stock Is Rapidly Approaching Buy Territory

    By Bob Ciura - July 22, 2013 | Tickers: ISRG, JNJ, MAKO

    Health-care stock Intuitive Surgical (NASDAQ: ISRG) used to be a favorite among growth investors just a few quarters ago. The company grew sales and profits at double-digit rates like clockwork and had a soaring share price reflecting its outstanding results.

    All that has changed, and the good times seem like an eternity ago. The company’s newly released quarterly results confirmed what investors had feared about the state of its more »

  • The Diabetes Pipeline With a Clog

    By Brandy Betz - July 22, 2013 | Tickers: AZN, BMY, LLY, JNJ

    Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE: JNJ), Eli Lilly (NYSE: LLY), and the partnership of Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). But the path to market proved tricky.

    Johnson and Johnson's Invokana earlier this year became the first SGLT2 approved in the United States. Bristol-Myers and AstraZeneca’s more »

  • Large Cap Stocks Are Cheaper Than They Appear

    By Ted Cooper - July 22, 2013 | Tickers: JNJ, MRK, PFE

    Uncertainty creates opportunity for long-term investors, and there is a lot of uncertainty in the healthcare sector right now. As a result, opportunistic investors should take a closer look at companies in this sector.

    Companies like Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), and Pfizer (NYSE: PFE) may be well followed, but, even so, the market sometimes underestimates their earning power. The patent cliff has created enormous uncertainty surrounding these more »

  • Billionaire Ken Fisher’s Healthcare Picks for Q3

    By Meena Krishnamsetty - July 21, 2013 | Tickers: GSK, JNJ, NVO, PFE, SNY

    In mid July, Fisher Asset Management, the asset management firm run by billionaire and Forbes columnist Ken Fisher, filed its 13F for the second quarter of 2013 with the SEC, disclosing many of its long equity positions as of the end of June. Insider Monkey tracks these filings in our database, using them to help us develop investment strategies (for example, we have found that the most popular small cap more »

  • Currency Headwinds Won't Stop These Stalwarts

    By Alexander Cho - July 19, 2013 | Tickers: KO, JNJ, SPY

    Part of the difficulty with analyzing equities is assessing the international strength of the economy. A strengthening dollar and falling emerging market GDP growth will have a negative impact on multinational companies.

    Global economic backdrop

    Source: Ycharts

    The iShares FTSE China ETF declined 22.61% year-to-date, iShares MSCI Brazil Capped ETF fell by 14.04% year-to-date, and the iShares MSCI Spain Capped Index Fund depreciated by 5.78% year-to-date.

    Brazil more »

  • Buffett's Exceptionally Poor Timing

    By Shmulik Karpf - July 19, 2013 | Tickers: BRK-B, JNJ

    Johnson & Johnson (NYSE: JNJ) has been a long-time darling of Warren Buffett's Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B). JNJ has long been considered the "blue chip" of the pharmaceutical world. With a great cash flow generation, a fortress-like balance sheet, and top-selling drugs such as Tylenol, JNJ was sure to outperform the market. Or at least that's what Buffett figured. This time, the Sage of Omaha got it more »

  • Expanding Labels to Expand Margins

    By Seth Robey - July 18, 2013 | Tickers: ABBV, AMGN, CELG, JNJ, ONXX, PFE

    In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health. Is cash being applied efficiently to maximize sales while minimizing the cost of R&D? Perhaps the most powerful way to maximize revenue potential and minimize cost is through label expansion.

    Companies with nascent revenue streams must appropriately limit costs while fostering newfound more »

  • 3 Key Takeaways From JNJ's Q2

    By Brandy Betz - July 18, 2013 | Tickers: LLY, JNJ, VRTX

    Johnson & Johnson (NYSE: JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion. The EPS was higher than analyst estimates, and the company upped its full-year guidance.

    But the details are where things get interesting. Here are three key takeaways from the earnings report -- and what they mean for Johnson & Johnson’s future.

    1. Infectious disease and more »

  • Is Time Running Out for This Fallen Biotech?

    By Sherrie Stone - July 17, 2013 | Tickers: DNDN, JNJ, MDVN

    There’s a lot to notice from Johnson & Johnson’s (NYSE: JNJ) earnings -- the company announced a very solid quarter. But the one thing that really stood out is the high sales that the company produced from its prostate cancer drug Zytiga. Does Zytiga's succes further indicate that time is running out for Dendreon’s (NASDAQ: DNDN) Provenge?

    Zytiga’s not slowing down

    Johnson & Johnson’s total sales for more »

  • Page 2 of 29